Ironwood Pharmaceuticals Inc (IRWD, Financial) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $91.25 million, and the earnings are expected to come in at $0.08 per share. The full year 2024's revenue is expected to be $357.18 million and the earnings are expected to be $0.25 per share. More detailed estimate data can be found on the Forecast page.
Ironwood Pharmaceuticals Inc (IRWD, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Ironwood Pharmaceuticals Inc (IRWD) for the full year 2024 have declined from $410.05 million to $357.18 million, and for 2025, the estimates have decreased from $464.50 million to $363.27 million. Earnings estimates for the full year 2024 have also been revised downward from $0.65 per share to $0.25 per share, and for 2025, from $0.84 per share to $0.49 per share.
Ironwood Pharmaceuticals Inc (IRWD, Financial) Reported History
In the previous quarter of June 30, 2024, Ironwood Pharmaceuticals Inc's (IRWD) actual revenue was $94.40 million, which missed analysts' revenue expectations of $106.996 million by -11.78%. Ironwood Pharmaceuticals Inc's (IRWD) actual earnings were -$0.01 per share, which missed analysts' earnings expectations of $0.177 per share by -105.65%. After releasing the results, Ironwood Pharmaceuticals Inc (IRWD) was down by -32.61% in one day.
Ironwood Pharmaceuticals Inc (IRWD, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 6 analysts, the average target price for Ironwood Pharmaceuticals Inc (IRWD) is $12.67 with a high estimate of $23 and a low estimate of $5. The average target implies an upside of 182.11% from the current price of $4.49.
Based on GuruFocus estimates, the estimated GF Value for Ironwood Pharmaceuticals Inc (IRWD, Financial) in one year is $10.60, suggesting an upside of 136.08% from the current price of $4.49.
Based on the consensus recommendation from 7 brokerage firms, Ironwood Pharmaceuticals Inc's (IRWD, Financial) average brokerage recommendation is currently 1.9, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
